DC excipient

Formulation Challenges in Low-Dose Fixed-Dose Combinations Developing fixed-dose combination (FDC) therapies presents unique formulation challenges, particularly when one active pharmaceutical...

Abstract Excipients are indispensable components of pharmaceutical dosage forms, significantly influencing product quality, safety, and performance. Conventional single excipients often...

Abstract Continuous Direct Compression via Mini-Batch Blending (CDC via MBB) is gaining traction as an innovative manufacturing technology in the...

Abstract In recent years, the environmental assessment and optimization of pharmaceutical dosage forms have received increasing attention. Consequently, interest in...

See the latest edition of the Fuji Chemical Technical Newsletter: THE POLYMORPHISM CHALLENGE IN BILASTINE FORMULATION Bilastine is a second-generation,...

Abstract Purposes The tabletability flip phenomenon (TFP), where an active pharmaceutical ingredient (API) with poorer tabletability exhibits better tabletability when...

See the latest edition of the Fuji Chemical Technical Newsletter: Why Etoricoxib is Difficult to Formulate? Etoricoxib, a selective COX-2...

Compritol® 888 ATO: one excipient benefits all, from formulator to end-user Compritol® 888 ATO With a drug release governed by...

Abstract The pharmaceutical industry is increasingly adopting co-processed excipients as alternatives to conventional excipients in tablet manufacturing despite certain regulatory...

Abstract Much of the remarkable advancements in oral peptide delivery have been achieved through the use of chemical permeation enhancers,...